{
    "id": 3523,
    "fullName": "FGFR4 amp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "FGFR4 amp indicates an increased number of copies of the FGFR4 gene. However, the mechanism causing the increase is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 2264,
        "geneSymbol": "FGFR4",
        "terms": [
            "FGFR4",
            "CD334",
            "JTK2",
            "TKF"
        ]
    },
    "variant": "amp",
    "createDate": "03/05/2015",
    "updateDate": "11/29/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 11181,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Balversa (erdafitinib) inhibited proliferation of a rhabdomyosarcoma cell line with FGFR4 amplification in culture, and inhibited tumor growth in xenograft models (PMID: 28341788).",
            "molecularProfile": {
                "id": 3330,
                "profileName": "FGFR4 amp"
            },
            "therapy": {
                "id": 1028,
                "therapyName": "Erdafitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3247,
                "name": "rhabdomyosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9140,
                    "pubMedId": 28341788,
                    "title": "Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28341788"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2061,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, BGJ398 demonstrated safety and preliminary efficacy in patients with select solid tumors harboring FGFR alterations (Cancer Res October 1, 2014 74:CT326).",
            "molecularProfile": {
                "id": 3330,
                "profileName": "FGFR4 amp"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 2252,
                    "pubMedId": null,
                    "title": "Abstract CT326: Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors",
                    "url": "http://cancerres.aacrjournals.org/content/74/19_Supplement/CT326.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9739,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with head and neck carcinoma harboring an FGFR4 amplification demonstrated a reduction in tumor size when treated with BGJ398 (PMID: 27870574).",
            "molecularProfile": {
                "id": 3330,
                "profileName": "FGFR4 amp"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 1542,
                "name": "head and neck carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7516,
                    "pubMedId": 27870574,
                    "title": "Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27870574"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 3330,
            "profileName": "FGFR4 amp",
            "profileTreatmentApproaches": [
                {
                    "id": 1504,
                    "name": "FGFR Inhibitor (Pan)",
                    "profileName": "FGFR4 amp"
                },
                {
                    "id": 1505,
                    "name": "FGFR4 Inhibitor",
                    "profileName": "FGFR4 amp"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}